Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Nanomedicine for cancer diagnosis and therapy / / Arshi Malik, Sarah Afaq and Mohammed Tarique (editors)
| Nanomedicine for cancer diagnosis and therapy / / Arshi Malik, Sarah Afaq and Mohammed Tarique (editors) |
| Pubbl/distr/stampa | Gateway East, Singapore : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (251 pages) |
| Disciplina | 616.994075 |
| Soggetto topico |
Nanomedicine
Cancer - Treatment - Technological innovations Nanomedicina Oncologia Terapèutica |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 981-15-7564-9 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Contents -- About the Editors -- 1: Nanoparticles for Cancer Therapy -- 1.1 Introduction -- 1.1.1 Cancer and its Types -- 1.1.2 Nanomedicine -- 1.2 Evolution of Cancer Therapy -- 1.2.1 Surgery and Adjuvant Therapies -- 1.2.2 Hormone Therapy -- 1.2.3 Immunotherapy -- 1.2.4 Cancer Therapy with Nanomedicine -- 1.3 Nanoparticles in Cancer Therapy -- 1.3.1 Protein Nanoparticles -- 1.3.2 Magnetic Nanoparticles -- 1.3.3 Inorganic Nanoparticles -- 1.3.4 Lipid Nanoparticles -- 1.3.5 Targeted Nanoparticles -- 1.3.6 Polymeric Nanoparticles -- 1.3.7 Multifunctional Nanoparticles -- 1.3.8 Quantum Dots -- 1.3.9 DNA Nanoparticles -- 1.4 Pharmacokinetics of Cancer Nanodrug Carriers -- 1.5 Cancer Nanomedical Research -- 1.5.1 Initial Advancements in Nanoparticle Research -- 1.5.2 Nanomedical Research Using Plant-Derived Compounds -- 1.5.3 Nanomedical Research Using Gene Therapeutic Strategies -- 1.5.4 Nanomedical Research Using In Vivo Imaging Techniques -- 1.5.5 Mainstream Research in the ``Golden Age´´ of Nanotechnology -- 1.5.6 Nanomedical Research Using Computational and Nanobioinformatic Tools -- 1.6 Nanomedicine in Cancer Diagnosis and Treatment -- 1.6.1 Immunoassays Using Nanomaterial-Embedded Microchips -- 1.6.2 In Vivo Imaging Using Nanoparticle Contrast Agents -- 1.6.3 Theranostic Nanomedicine -- 1.6.4 Cancer Nanodrug Release Systems and Personalized Cancer Nanomedicine -- 1.7 Current Research and Prospects -- 1.7.1 Smart Nanocarrier-Based Drug-Delivery Systems for Cancer Therapy -- 1.7.2 RNA Delivery Using Nanoparticles -- 1.7.3 Nanobots -- 1.8 Concluding Remarks -- References -- 2: Strategies for Improving the Efficiency of Nanomaterials -- 2.1 Introduction -- 2.2 Strategies for the Improvement of Nanomaterials -- 2.2.1 Photocatalytic Efficiency -- 2.2.2 Therapeutic Efficiency.
2.2.2.1 Strategic Improvement of Nanomaterials for Enhanced Permeability and Retention (EPR) Effects -- 2.2.2.2 Strategic Improvement of Nanomedicine for Improved Drug Delivery Systems -- Liposome Based Nanoformulation -- Nanoemulsions -- Solid Lipid Nanoparticles (SLN) -- Strategies for Organelles Specific Targeting of Nanodrugs -- Virus Based Nanoformulation -- 2.2.2.3 Photoactivated Nanomaterials for Photodynamic and Photothermal Therapy (PDT/PTT) -- 2.2.2.4 Mesoporous Silica Nanoparticles (MSNP) -- 2.2.2.5 Dendrimers -- 2.2.3 Engineering Nanoparticles to Evade the Multidrug Resistance (MDR) in Cancer -- 2.2.4 Nanoparticle-Based Combination Therapy -- 2.3 Conclusion -- References -- 3: Bioinspired Nanoparticles in Cancer Theranostics -- 3.1 Introduction -- 3.2 Novelty of Bioinspired Nanoparticles Based Theranostics -- 3.2.1 Liposomes in Cancer Theranostics -- 3.2.2 Lipid Nanoparticles in Cancer Theragnostic -- 3.2.2.1 Solid Lipid Nanoparticles (SLNs) -- 3.2.2.2 Nano-Structured Lipids (NLCs) -- 3.2.2.3 Lipid Nanocapsules (LNCs) -- 3.2.3 Protein-Based Nanoparticles for Cancer Theranostics -- 3.2.4 Virus like Nanoparticles in Cancer Theranostics -- 3.2.5 Inorganic and Bionanoparticles in Cancer Theranostics -- 3.3 Conclusions and Future Perspectives -- References -- 4: Nanomedicines for Solid Tumors: Current Status, Challenges, and Future Prospects -- 4.1 Introduction -- 4.2 Possible Factors that Initiate Cancer Growth -- 4.2.1 Age -- 4.2.2 Cancer Causing Elements -- 4.2.3 Immunosuppression -- 4.2.4 Infectious Agents -- 4.2.5 Radiation -- 4.3 Tumor Classification Based on Tissue of Origin -- 4.4 Existing Treatment Options Available for Cancer -- 4.5 Description of Solid Tumor -- 4.6 Nanomedicine -- 4.6.1 Unlocking Novel Cancer Applications Exploited in the Field of Nanomedicine -- 4.7 Fabrications of Nanocarrier for Drug Delivery. 4.8 Targeted Delivery of Nanocarrires to the Tumor Niche as Well as Solid Tumor -- 4.8.1 Drug Targeting Mechanisms and Surface Functionalization of Nanocarriers Aiding Nanomedicine Based Technologies in Solid ... -- 4.9 Nanoscience Based Imaging Technologies in the Detection of Solid Tumors -- 4.9.1 Photodynamic Nanomedicine in the Treatment of Solid Tumors -- 4.10 Nanomedicine and Solid Tumor Heterogenecity -- 4.11 Nanomedicine in Solid Tumors: PROS and CONS? -- 4.11.1 PROS -- 4.11.2 CONS -- 4.12 Discussion -- 4.13 Future Perspective -- References -- 5: Nanomaterials for Early Cancer Diagnostics -- 5.1 Introduction -- 5.2 Cancer and Biomarkers -- 5.2.1 Early Detection of Prostate Cancer -- 5.2.2 Early Detection of Breast Cancer -- 5.2.3 Early Detection of Lung Cancer -- 5.2.4 Early Detection of Liver Cancer -- 5.2.5 Early Detection of Oral Cancer -- 5.2.6 Early Detection of Pancreatic Cancer -- 5.2.7 Early Detection of Ovarian Cancer -- 5.2.8 Early Detection of Human Cervical Cancer -- 5.2.9 Early Detection of Bladder Cancer -- 5.2.10 Early Detection of Head and Neck Cancer -- 5.2.11 Early Detection of Colon Cancer -- 5.3 Conclusion -- References -- 6: Role of Nanomedicine for Cancer Immunotherapy -- 6.1 Introduction -- 6.2 Improving Cellular-Mediated Immunotherapy -- 6.2.1 Combining Therapeutic Agents to Immune Cells -- 6.2.2 Directing Therapeutic Drugs to Immune Cells -- 6.2.3 Delivery of Gene in Lymphocytes -- 6.3 Delivery Mechanism of Nanoparticle Therapeutics -- 6.3.1 Stimulating Immunogenic Cell Death (ICD) -- 6.3.1.1 Nanosized Drug Carriers -- 6.3.1.2 Nanopulse Stimulation -- 6.3.2 Enhanced Presentation of Ligands to Immune Cells -- 6.3.3 Chronological Regulation of Immunostimulation -- 6.4 Modulation in Pharmacokinetics of Immunotherapy Agents -- 6.5 Targeting Myeloid Cells -- 6.6 Targeting Stromal Cell in TME. 6.7 Limitations of Nanomedicines in Cancer Immunotherapy -- 6.8 Conclusion and Future Perspectives -- References -- 7: Targeting Tumor Microenvironment Through Nanotheranostics -- 7.1 Introduction -- 7.2 The Tumor Microenvironment (TME) and its Components -- 7.2.1 Cells of the Immune System -- 7.2.1.1 The T Cells -- 7.2.1.2 The B Cells -- 7.2.1.3 Tumor Associated Macrophages (TAMs) -- 7.2.1.4 Tumor Associated Neutrophils (TANs) -- 7.2.1.5 Natural Killer (NK) Cells -- 7.2.1.6 Cancer Associated Fibroblasts (CAFs) -- 7.2.2 The Extracellular Matrix (ECM) and Surrounding Cells -- 7.2.2.1 The Adipocytes -- 7.2.2.2 The Pericytes -- 7.2.2.3 Matrix Metalloproteases (MMPs) and Other Proteases -- 7.2.2.4 The Endothelial Cells -- 7.2.3 The TME, Inflammation, and Cancer -- 7.2.4 Hypoxia in the TME -- 7.3 The TME as an Attractive Therapeutic Target in Cancer -- 7.4 Cancer Nanotheranostic Agents that Target the TME -- 7.4.1 Metallic Nanoparticles (NPs) -- 7.4.2 Magnetic Nanoparticles (MNPs) -- 7.4.3 Mesoporous Silica Nanoparticles (MSiNPs) -- 7.4.4 Nano-Graphenes (NGs) -- 7.4.5 Polymeric-Based Nanotheranostic Particles (PNPs) -- 7.4.6 Lipid-Based Nanotheranostic Particles (LNPs) -- 7.4.7 Protein-Based Nanotheranostic Particles (PNPs) -- 7.4.8 Viral-Based Nanotheranostic Particles (VLPs) -- 7.4.9 DNA-Based Cancer Nanotheranostic Platform -- 7.5 Visualizing Cancer Through Nanotheranostics -- 7.5.1 Magnetic Resonance Imaging (MRI) -- 7.5.2 Photoacoustic Imaging (PAI) -- 7.5.3 Optical Imaging -- 7.5.4 Nuclear Imaging -- 7.6 Nanotheranostics for the Detection of Cancer Biomarkers -- 7.6.1 Labeling Nanoparticles with Conjugates -- 7.6.1.1 Chemical Crosslinking -- 7.6.1.2 Biotin/Avidin Conjugation -- 7.6.1.3 Click Chemistry -- 7.6.2 Target Moieties for Identification of Cancer Biomarkers -- 7.7 Conclusion and Future Direction -- References. 8: Therapeutic Applications of Noble Metal (Au, Ag, Pt)-Based Nanomedicines for Melanoma -- 8.1 Introduction -- 8.1.1 Melanoma -- 8.1.1.1 Global Statistics and Market -- 8.1.1.2 Treatment Strategies -- 8.1.2 Nanotechnology in Melanoma -- 8.1.2.1 Nanoparticles for Melanoma -- 8.1.2.2 PAMAM -- 8.1.2.3 Zinc Oxide Nanoparticle -- 8.1.2.4 Titanium Dioxide Nanoparticle -- 8.1.2.5 Vanadium Pentoxide Nanoparticle -- 8.1.2.6 Copper Prussian Blue Nanoparticle -- 8.2 Importance of Noble Metal Nanoparticles in Biomedicine -- 8.3 Role of Noble Metals (Au, Ag, Pt) in Treatment of Melanoma -- 8.3.1 Gold (Au) Nanoparticles -- 8.3.1.1 Drug Delivery -- 8.3.1.2 Gene Delivery and Immunotherapy -- 8.3.1.3 Biosynthesized Gold Nanoparticles -- 8.3.1.4 Imaging -- 8.3.1.5 Photothermal and Photodynamic Therapy -- 8.3.2 Silver (Ag) Nanoparticles -- 8.3.3 Platinum (Pt) Nanoparticles -- 8.4 Toxicity of Noble Metal Nanoparticles -- 8.5 Challenges and Future Perspectives -- 8.6 Conclusion -- References -- 9: Ethics in Nanomedicine -- 9.1 Introduction -- 9.2 Nanomedicine -- 9.3 Difference Between Nanotechnology and Nanomedicine -- 9.4 Hype Versus Reality of Nanomedicine -- 9.5 Nondiscrimination and Integrity of Nanomedicine -- 9.6 The Potentiality of Nanomedicine -- 9.7 Biocompatibility and Toxicity of Nanostructures -- 9.8 Demand of the Nanomedicine in Market -- 9.9 Nanomedicine and Ethical Concerns -- 9.9.1 Ethical Problems Associated with Translational Research Involving Nanomedicine -- 9.9.2 Ethical Problems in Personalized and Regenerative Therapy with Nanomedicine -- 9.9.3 Ethical Concerns of Medical Surveillance -- 9.9.4 Ethical Challenges Inherent to Nanomedicine Applications -- 9.9.5 Social Ethics in Public Health Systems -- 9.9.5.1 Impact of Nanotechnology in Developing Nations -- 9.9.5.2 Impact of Nanotechnology on Laborers and Managerial Issues. 9.10 Future Perspectives. |
| Record Nr. | UNINA-9910488707403321 |
| Gateway East, Singapore : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Natural products and human diseases : pharmacology, molecular targets, and therapeutic benefits / / edited by Amirhossein Sahebkar and Thozhukat Sathyapalan
| Natural products and human diseases : pharmacology, molecular targets, and therapeutic benefits / / edited by Amirhossein Sahebkar and Thozhukat Sathyapalan |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2022] |
| Descrizione fisica | 1 online resource (545 pages) |
| Disciplina | 615.3 |
| Collana | Advances in Experimental Medicine and Biology |
| Soggetto topico |
Biochemical markers
Natural products Terapèutica |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-73234-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910520090203321 |
| Cham, Switzerland : , : Springer, , [2022] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
New Therapies to Prevent or Cure Auditory Disorders [[electronic resource] /] / edited by Sylvie Pucheu, Kelly E. Radziwon, Richard Salvi
| New Therapies to Prevent or Cure Auditory Disorders [[electronic resource] /] / edited by Sylvie Pucheu, Kelly E. Radziwon, Richard Salvi |
| Edizione | [1st ed. 2020.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2020 |
| Descrizione fisica | 1 online resource (VII, 186 p. 29 illus., 25 illus. in color.) |
| Disciplina | 617.8 |
| Soggetto topico |
Neurosciences
Otorhinolaryngology Malalties de l'orella Medicina preventiva Terapèutica |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-40413-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Intro -- Introduction -- Contents -- Lifestyle Intervention to Prevent Age-Related Hearing Loss: Calorie Restriction -- 1 Introduction -- 2 Effects of Age on Auditory Function -- 3 Effects of Calorie Restriction on Aging -- 3.1 Types of Calorie Restriction Regimens -- 3.2 Effects of Calorie Restriction on Hearing Loss in Laboratory Animals -- 4 Mechanisms Underlying the Beneficial Effects of CR on AHL -- 4.1 Oxidative Stress -- 4.2 Apoptosis -- 4.3 mtDNA Mutations -- 5 Conclusion -- References -- Noise-Induced Hearing Loss and Drug Therapy: Basic and Translational Science -- 1 Introduction 2 Cochlear Pathology -- 2.1 Oxidative Stress -- 2.2 Cochlear Blood Flow Changes -- 2.3 Apoptotic Cell Death -- 2.4 Mechanical Damage and Stereocilia Injury -- 3 Noise-Induced Deafferentation -- 3.1 Consequences of Synaptopathy -- 4 Auditory Threshold Shift as a Measure of Noise-Induced Hearing Loss -- 4.1 Extended High-Frequency Audiometry -- 5 Effects of Noise on Suprathreshold Measures of Hearing -- 5.1 Speech-in-Noise Testing -- 6 Pharmaceutical Otoprotection from Noise-Induced Hearing Loss -- 6.1 Antioxidants -- 6.2 Steroid Therapy -- 6.3 S-Ketamine and Glutamate Excitotoxicity 6.4 Cell Death and Stress Inhibitors -- 7 Summary -- References -- Review of Ototoxic Drugs and Treatment Strategies for Reducing Hearing Loss -- 1 Significance and Background -- 2 Cisplatin Ototoxicity -- 2.1 Entry of Cisplatin into the Cochlea -- 2.2 Mechanisms Underlying Cisplatin Ototoxicity -- Increased Oxidative Stress -- Promoting Cellular Apoptosis -- Covalent Modification of DNA -- 2.3 Pharmacogenomics of Cisplatin Ototoxicity -- 2.4 Approaches to Treating Cisplatin Ototoxicity -- Relieving Oxidative Stress -- Targeting Cochlear Inflammation Drugs Targeting G Protein-Coupled Receptors for Treating Cisplatin Ototoxicity -- 2.5 Ongoing Clinical Trials for Cisplatin Ototoxicity -- 3 Cyclodextrin-Induced Hearing Loss -- 4 Aminoglycosides -- 4.1 Overview -- 4.2 Studies Showing Hearing Loss -- 4.3 Uptake of Aminoglycosides into the Cochlea -- 4.4 Aminoglycoside Genetic Susceptibility -- 4.5 Preventative Strategies for Ototoxicity -- Antioxidants -- Inhibition of Apoptosis -- Mechanoelectrical Transducer Channel Blockers -- 5 Summary -- References -- Approaches to Regenerate Hair Cell and Spiral Ganglion Neuron in the Inner Ear 1 Introduction -- 1.1 Global Estimates and Impact of Hearing Impairment -- 1.2 Categories of Hearing Loss -- 1.3 Native HCs Regeneration Capacity in Mammals and Non-mammals -- 2 Approaches to Regenerate HCs and SGNs -- 2.1 Gene Therapy -- Cochlear Gene Therapy Vehicles -- 2.2 Key Signaling Pathway Genes for HC Regeneration -- 2.3 Atoh1-Based Gene Therapy -- 2.4 Inactivation of Cell Cycle Inhibitors Based Gene Therapy -- 2.5 Gene Therapy for SGN Regeneration -- 3 Stem Cell Therapy -- 4 Conclusion -- References. |
| Record Nr. | UNINA-9910409701503321 |
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2020 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Ovarian cancer : molecular & diagnostic imaging and treatment strategies / / Heide Schatten, editor
| Ovarian cancer : molecular & diagnostic imaging and treatment strategies / / Heide Schatten, editor |
| Edizione | [1st ed. 2021.] |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (VIII, 178 p. 43 illus., 33 illus. in color.) |
| Disciplina | 616.99465 |
| Collana | Advances in Experimental Medicine and Biology |
| Soggetto topico |
Ovaries - Cancer
Càncer d'ovari Diagnòstic Terapèutica |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-73359-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | 1. Current and Futuristic Roadmap of Ovarian Cancer Management: An Overview -- 2. Epithelial ovarian cancer and cancer stem cells -- 3. Ovarian Cancer: Therapeutic Strategies to Overcome Immune Suppression -- 4. Pharmacological effects of natural components against ovarian cancer and mechanisms -- 5. Modeling the Early Steps of Ovarian Cancer Dissemination in an Organotypic Culture of the Human Peritoneal Cavity -- 6. PAX8, an emerging player in Ovarian Cancer -- 7. Single Cell RNA Sequencing of Ovarian Cancer: Promises and Challenges.-8. Enforced expression of METCAM/MUC18 decreases in vitro motility and invasiveness and tumorigenesis and in vivo tumorigenesis of human ovarian cancer BG-1 cells -- 9. 3D Models for Ovarian Cancer -- 10. Ovarian Cancer Stem Cells: Characterization and Role in Tumorigenesis. |
| Record Nr. | UNINA-9910495200903321 |
| Cham, Switzerland : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Penile carcinoma : therapeutic principles and advances / / edited by Philippe E. Spiess and Andrea Necchi
| Penile carcinoma : therapeutic principles and advances / / edited by Philippe E. Spiess and Andrea Necchi |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (156 pages) |
| Disciplina | 616.99463 |
| Soggetto topico |
Penis - Cancer - Treatment
Penile Neoplasms - therapy Malalties del penis Càncer genitourinari Terapèutica |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-82060-2 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910502991003321 |
| Cham, Switzerland : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Polymeric nanoparticles for the treatment of solid tumors [[electronic resource] /] / edited by Santwana Padhi, Anindita Behera, Eric Lichtfouse
| Polymeric nanoparticles for the treatment of solid tumors [[electronic resource] /] / edited by Santwana Padhi, Anindita Behera, Eric Lichtfouse |
| Edizione | [1st ed. 2022.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2022 |
| Descrizione fisica | 1 online resource (515 pages) |
| Disciplina | 616.99406 |
| Collana | Environmental Chemistry for a Sustainable World |
| Soggetto topico |
Medicine—Research
Biology—Research Nanotechnology Cancer—Treatment Biomedical Research Cancer Therapy Nanopartícules Càncer Terapèutica |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-031-14848-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Chapter 1. The tumor microenvironment -- Chapter 2. Methods of formulation of polymeric nanoparticles -- Chapter 3. Natural polymers based nanoparticles targeted to solid tumors -- Chapter 4. Optimization of physicochemical properties of polymeric nanoparticles for targeting solid tumors -- Chapter 5. Passive and active targeting approaches for solid tumors -- Chapter 6. Polymeric nanoparticles entrapping natural drugs for cancer therapy -- Chapter 7. Polymeric nanoparticles entrapping drug combinations targeted to solid tumors -- Chapter 8. Ligands specific to over-expressed receptors in solid tumors -- Chapter 9. Ligand targeted polymeric nanoparticles for cancer chemotherapy -- Chapter 10. Polymeric nanoparticles as theranostics for targeting solid tumors -- Chapter 11. Oral delivery of polymeric nanoparticles for solid tumors -- Chapter 12. Polymeric nanoparticles to target glioblastoma tumors -- Chapter 13. Polymeric nanoparticles to target lung cancer -- Chapter 14. Polymer based nanoplatforms for targeting breast cancer -- Chapter 15. PH-Sensitive polymeric nanoparticles for cancer treatment -- Chapter 16. Polymeric nanoplatforms for targeted treatment of prostate cancer -- Chapter 17. Cellular internalization and toxicity of polymeric nanoparticles -- Chapter 18. Prospects and challenges in the treatment of solid tumors. |
| Record Nr. | UNINA-9910631081103321 |
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2022 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Practice of sleep medicine : sleep disorders in children and adults / / Boris A. Stuck [and four others]
| Practice of sleep medicine : sleep disorders in children and adults / / Boris A. Stuck [and four others] |
| Autore | Stuck Boris A. |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (298 pages) |
| Disciplina | 616.8498 |
| Soggetto topico |
Sleep disorders
Sleep disorders in children Trastorns del son Terapèutica |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-17412-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Contents -- About the Authors -- 1: Physiological Basics of Healthy and Disturbed Sleep -- 1.1 History of Sleep Medicine -- 1.2 Classification of Sleep Disorders -- 1.3 Phenomenology of Sleep -- 1.4 Physiological Alterations During Sleep -- 1.4.1 Cardiovascular System During Sleep -- 1.4.2 Thermoregulation -- 1.4.3 Hormone System and Sleep -- 1.5 Circadian Rhythm -- 1.6 Sleep Regulation -- 1.7 Functions of Sleep -- 1.8 Dreaming -- 1.8.1 Definitions -- 1.8.2 Dream Recall -- 1.8.3 General Characteristics of Dreams -- 1.8.4 Correlation Between Wakefulness and Dream -- 1.8.5 Function of Dreams -- 1.9 Questions -- Further Reading -- 2: Diagnostic Methods -- 2.1 History Taking -- 2.1.1 Sleep-Related Personal Anamnesis -- 2.1.2 Sleep-Related History Compiled by Third Parties -- 2.1.3 History Taking Regarding Sleepiness, Fatigue, and Daytime Performance -- 2.1.4 Further History Taking for Differential Diagnostic: Assessment of Possible Origins of Sleep Disorders -- 2.2 Laboratory Parameters for Sleep Disorders -- 2.3 Sleep Questionnaire -- 2.3.1 Insomnia Questionnaire -- 2.3.2 Questionnaires for the Assessment of Sleep-Related Breathing Disorders -- 2.3.3 Questionnaire Regarding Restless Legs Syndrome -- 2.4 Physical Examination -- 2.5 Actigraphy -- 2.6 Outpatient Step-by-Step Diagnostics for Sleep-Related Breathing Disorders and Polygraphy Systems -- 2.7 Polysomnography (PSG) -- 2.7.1 Standard Parameters of Polysomnography (PSG) -- 2.7.1.1 Measurement of Blood Pressure During Sleep -- 2.7.2 Parameters to Be Reported for Polysomnography (PSG) -- 2.7.2.1 Sleep Scoring Data -- 2.7.2.2 Phenomenology and Classification of Arousals -- 2.7.3 Polysomnography (PSG) in Patients with Insomnia -- 2.7.4 Polysomnography (PSG) in Patients with Periodic Limb Movements in Sleep and Patients with Restless Leg Syndrome.
2.7.5 Polysomnography (PSG) in Cases of Bruxism -- 2.7.6 Polysomnography (PSG) in Cases of REM Behavior Disorders -- 2.7.7 Polysomnography (PSG) in Cases of Rhythmic Movement Disorders in Sleep -- 2.7.8 Polysomnography (PSG) in Cases of Sleep-Related Breathing Disorders -- 2.8 Examination of Sleepiness- and Fatigue-Related Daytime Impairments -- 2.8.1 Diagnostics of Daytime Sleepiness -- 2.8.1.1 Diagnostic Procedures of Central Nervous System Alertness -- Multiple Sleep Latency Test (MSLT) -- Maintenance of Wakefulness Test (MWT) -- Pupillographic Sleepiness Test -- 2.8.1.2 Diagnostic Procedures to Assess Vigilance -- Vigilance Test According to Quatember and Maly -- Sub-test of Vigilance of the Test Battery for Attentional Performance -- 2.8.1.3 Diagnostic Procedures to Assess Selective Attention -- Achievement Motivation Test Series, Version 3.00 of the Vienna Test System -- Go/NoGo of the Test Battery for Attentional Performance -- 2.8.1.4 Diagnostic Procedures to Assess Divided Attention -- Test of Divided Attention of the Test Battery for Attentional Performance -- Vienna Determination Unit -- 2.8.1.5 Subjective Diagnostic Questionnaires for Assessment of Sleepiness-Related Impairments -- Stanford Sleepiness Scale (SSS) -- Epworth Sleepiness Scale (ESS) -- 2.9 Questions -- Further Reading -- 3: Insomnia -- 3.1 Classification of Insomnia Disorders -- 3.2 Chronic Insomnia Disorder -- 3.2.1 Definitions -- 3.2.1.1 Subtype of Psychophysiological Insomnia -- 3.2.1.2 Subtype of Paradoxical Insomnia -- 3.2.1.3 Subtype of Idiopathic Insomnia -- 3.2.1.4 Subtype of Insomnia Caused by a Mental Disorder -- 3.2.1.5 Subtype of Insomnia Resulting from Inadequate Sleep Hygiene -- 3.2.1.6 Subtype of Insomnia due to Psychiatric Disease, Medical Condition, or Drug and Substance Consumption -- 3.2.2 Etiology and Pathogenesis. 3.2.2.1 Developmental Model of Chronic Insomnia -- 3.2.2.2 Risk Factors for the Development of Chronic Insomnia -- 3.2.3 Polysomnographic Findings -- 3.3 Short-Term Insomnia Disorder -- 3.4 Other Insomnia Disorders -- 3.5 Isolated Symptoms and Normal Variants -- 3.5.1 Excessive Time in Bed -- 3.5.2 Short Sleeper -- 3.6 Diagnostics of Insomnia -- 3.7 Therapy of Insomnia -- 3.7.1 Psychoeducation -- 3.7.1.1 Information About Sleep -- 3.7.1.2 Inadequate Behaviors Related to Insomnia -- 3.7.1.3 Good Sleep Hygiene -- 3.7.2 Cognitive-behavioral Therapy of Insomnia -- 3.7.2.1 Bedtime Rituals -- 3.7.2.2 Cognitive Techniques -- Cognitive Restructuring -- Rumination Chair -- Stopping Thoughts -- 3.7.2.3 Sleep Restriction -- 3.7.2.4 Stimulus Control -- 3.7.2.5 Group Therapy and Insomnia Workshops -- 3.7.3 Pharmacotherapy of Insomnia -- 3.7.3.1 Benzodiazepine Receptor Agonists (BZRAs) -- 3.7.3.2 Benzodiazepines (BZDs) -- 3.7.3.3 Treatment Strategies Regarding BZDs and BZRAs -- Standard Interval Therapy -- Controlled Interval Therapy -- Quota-Interval Therapy -- Low-Dose Long-Term Therapy -- Low-Dose Combination Therapy -- 3.7.3.4 Melatonin and Melatonin Receptor Agonists -- 3.7.3.5 Hypocretin/Orexin Antagonists -- 3.7.3.6 Second-line Hypnotics -- Antidepressants -- Neuroleptics -- Antihistamines -- Alcohol Derivatives -- Phytotherapeutics -- 3.8 Questions -- Further Reading -- 4: Sleep-Related Breathing Disorders -- 4.1 Breathing Disorders without Obstruction -- 4.1.1 Definitions -- 4.1.1.1 Central Sleep Apnea Syndromes -- 4.1.1.2 Sleep-Related Hypoventilation and Hypoxemia Syndrome -- 4.1.2 Etiology and Pathophysiology -- 4.1.2.1 Regulation of Breathing -- 4.1.2.2 Central Sleep Apnea Syndrome -- 4.1.2.3 Hypoventilation or Hypoxemia Syndromes -- 4.1.3 Epidemiology -- 4.1.4 Clinical Presentation. 4.1.4.1 Central Sleep Apnea Syndromes -- 4.1.4.2 Hypoventilation or Hypoxemia Syndromes -- 4.2 Obstructive Sleep-Related Breathing Disorders -- 4.2.1 Definitions -- 4.2.2 Etiology and Pathophysiology -- 4.2.2.1 Anatomical Models -- 4.2.2.2 Functional Models -- 4.2.3 Epidemiology -- 4.2.4 Clinical Presentation -- 4.3 Snoring -- 4.3.1 Definitions -- 4.3.2 Etiology and Pathophysiology -- 4.3.3 Epidemiology -- 4.3.4 Clinical Presentation -- 4.4 Diagnostic Procedures -- 4.4.1 Examination Procedures and Sleep-Related Medical Diagnostics -- 4.4.1.1 Diagnostics in Cases of Central Sleep Apnea Syndromes -- 4.4.1.2 Diagnostics in Cases of Sleep-Related Hypoventilation or Hypoxemia Syndrome -- 4.4.1.3 Diagnostics in Cases of Obstructive Sleep Apnea -- 4.4.2 Differential Diagnoses -- 4.5 Therapeutic Principles -- 4.5.1 Therapeutic Principles in Cases of Snoring -- 4.5.2 Therapeutic Principles in Cases of Sleep Apnea -- 4.6 Ventilation Therapy -- 4.6.1 Different Types of Noninvasive Ventilation Therapy -- 4.6.1.1 Positive Pressure Ventilation in Cases of Spontaneously Breathing Patients -- CPAP -- APAP -- Bilevel-S -- C-Flex, EPR, SoftPAP, and A-Flex -- 4.6.1.2 Positive Pressure Ventilation in Cases of Disturbed Respiratory Drive -- Bilevel-T -- Bilevel-S/T -- 4.6.1.3 Positive Pressure Ventilation in Cases of Cheyne-Stokes Respiration -- 4.6.1.4 Practical Aspects -- 4.6.1.5 Accessories and Masks -- 4.6.1.6 Undesired Side Effects of Positive Pressure Ventilation -- 4.6.2 Ventilation Therapy in Cases of Central Sleep Apnea Syndromes -- 4.6.2.1 Primary Central Sleep Apnea and Central Sleep Apnea Due to a Medical Disorder -- 4.6.2.2 Cheyne-Stokes Respiration -- 4.6.3 Ventilation Therapy in Cases of Sleep-Related Hypoventilation and Hypoxemia. 4.6.3.1 Sleep-Related Hypoventilation and Hypoxemia Syndromes that Are Not Caused by Bronchial Obstruction -- 4.6.3.2 Sleep-Related Hypoventilation and Hypoxemia Caused by Bronchial Obstruction -- 4.6.4 Ventilation Therapy in Cases of Obstructive Sleep Apnea -- 4.6.4.1 Indication -- 4.6.4.2 Practical Aspects -- 4.6.4.3 Therapeutic Effects -- 4.7 Therapeutic Alternatives -- 4.7.1 Conservative Procedures -- 4.7.1.1 Weight Loss -- 4.7.1.2 Behavioral Changes -- 4.7.1.3 Medication -- 4.7.1.4 Nocturnal Oxygen Therapy -- 4.7.2 Device-Based Procedures -- 4.7.2.1 Increase of Muscle Tone -- 4.7.2.2 Avoiding the Supine Position -- 4.7.2.3 Mandibular Advancement Devices -- Practical Aspects -- Patient Selection -- Acceptance and Side Effects -- Therapeutic Effects -- 4.8 Surgical Therapy -- 4.8.1 Indications and Contraindications -- 4.8.2 Selection of the Surgical Therapy -- 4.8.3 Surgery of the Nose -- 4.8.4 Surgery of the Soft Palate -- 4.8.4.1 Surgical Treatment of the Soft Palate in Cases of Snoring -- Radiofrequency Surgery -- Soft Palate Implants -- 4.8.4.2 Surgical Treatment of the Soft Palate in Obstructive Sleep Apnea -- 4.8.5 Surgery of the Retrolingual Space -- 4.8.6 Hypoglossal Nerve Stimulation -- 4.8.7 Maxillofacial Surgery -- 4.9 Questions -- Further Reading -- 5: Hypersomnia Disorders -- 5.1 Narcolepsy -- 5.1.1 Definitions -- 5.1.2 Etiology and Pathophysiology -- 5.1.3 Epidemiology -- 5.1.4 Clinical Presentation -- 5.1.5 Diagnostic Procedures -- 5.1.6 Sleep Diagnostics -- 5.1.7 Differential Diagnostics -- 5.1.8 Therapy -- 5.1.8.1 Non-drug Therapy -- 5.1.8.2 Drug Therapy -- 5.1.8.3 Treatment of Comorbid Sleep Disorders -- 5.2 Idiopathic Hypersomnia -- 5.2.1 Definitions -- 5.2.2 Etiology and Pathophysiology -- 5.2.3 Epidemiology -- 5.2.4 Clinical Presentation -- 5.2.5 Diagnostics. 5.2.6 Sleep Diagnostics. |
| Record Nr. | UNINA-9910492142603321 |
Stuck Boris A.
|
||
| Cham, Switzerland : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Prevention and Treatment of Atherosclerosis [[electronic resource] ] : Improving State-of-the-Art Management and Search for Novel Targets / / edited by Arnold von Eckardstein, Christoph J. Binder
| Prevention and Treatment of Atherosclerosis [[electronic resource] ] : Improving State-of-the-Art Management and Search for Novel Targets / / edited by Arnold von Eckardstein, Christoph J. Binder |
| Autore | Eckardstein Arnold von |
| Edizione | [1st ed. 2022.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2022 |
| Descrizione fisica | 1 online resource (537 pages) |
| Disciplina | 616 |
| Altri autori (Persone) | BinderChristoph J |
| Collana | Handbook of Experimental Pharmacology |
| Soggetto topico |
Internal medicine
Pharmacology Diseases Internal Medicine Arterioesclerosi Terapèutica Medicina preventiva |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-86076-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Diet, Life Style, Smoking -- Blood Pressure Lowering -- Glycemic Control in Diabetes -- LDL-Cholesterol Lowering -- Antithrombotic Therapy (Platelet Inhibition, Anti-coagulation) -- Triglyceride Rich Lipoproteins -- HDL -- Lipoprotein(a) -- Obesity, Non-alcoholic Fatty Liver Disease, and Metabolic Syndrome -- Nutraceuticals / Functional Food -- Adipose Tissue (WAT, BAT) -- Microbiota and Cardiometabolic Disease -- SMCs, Matrix -- Immune Modulation -- NETs and Neutrophils -- Genomic Strategies Towards Identification of Novel Therapeutic Targets -- Non Coding RNAs -- Metabolomics, Lipidomics -- Epigenomics. |
| Record Nr. | UNINA-9910523787303321 |
|
Eckardstein Arnold von
|
||
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2022 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Prevention, recognition and management of fetal alcohol spectrum disorders / / Raja A.S. Mukherjee, Neil Aiton, editors
| Prevention, recognition and management of fetal alcohol spectrum disorders / / Raja A.S. Mukherjee, Neil Aiton, editors |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (479 pages) |
| Disciplina | 618.3268 |
| Soggetto topico |
Fetal alcohol spectrum disorders - Prevention
Fetal alcohol spectrum disorders - Diagnosis Fetal alcohol spectrum disorders - Treatment Alcoholisme en l'embaràs Efectes fisiològics Fetus Medicina preventiva Diagnòstic Terapèutica |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-73966-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910495163003321 |
| Cham, Switzerland : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Return to Sport after ACL Reconstruction and Other Knee Operations [[electronic resource] ] : Limiting the Risk of Reinjury and Maximizing Athletic Performance / / edited by Frank R. Noyes, Sue Barber-Westin
| Return to Sport after ACL Reconstruction and Other Knee Operations [[electronic resource] ] : Limiting the Risk of Reinjury and Maximizing Athletic Performance / / edited by Frank R. Noyes, Sue Barber-Westin |
| Edizione | [1st ed. 2019.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2019 |
| Descrizione fisica | 1 online resource (XX, 709 p. 301 illus., 267 illus. in color.) |
| Disciplina | 617.1027 |
| Soggetto topico |
Sports medicine
Orthopedics Rehabilitation Sports Medicine Genoll Cirurgia ortopèdica Terapèutica Medicina esportiva |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-22361-2 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Part I - Problems and Barriers for Successful Return to Sport -- 1.Advantages and Potential Consequences of Return to Sport After ACL Reconstruction: Quality of Life, Reinjury Rates, Knee Osteoarthritis -- 2. Common Symptom, Psychological, and Psychosocial Barriers to Return to Sport -- 3.The Arthritis Barrier: Long-Term Effects of ACL Trauma on Knee Joint Health -- Part II - Return to Sport: Whose Decision Is It? -- 4.Return to Sport Decision-Based Models -- 5.Role of the Team Physician, Orthopaedic Surgeon, and Rehabilitation Specialists -- 6.Return to Sport After Primary ACL Reconstruction in Amateur, Children, and Elite Athletes: Feasibility and Reinjury Concerns -- Part III - Spectrum of Optimal Treatment of ACL Injuries -- 7.What is the Scientific Basis for Knee Ligament Healing and Maturation to Restore Biomechanical Properties and a Return to Sports? -- 8.Preoperative Rehabilitation: Basic Principles -- 9.Extended Preoperative Rehabilitation: Does It Influence Return to Sport After Surgery? -- 10 -- Intraoperative Considerations Crucial for a Successful Outcome -- 11. Early Postoperative Rehabilitation to Avoid Complications and Prepare for Return to Sport Training -- 12.Early Postoperative Role of Blood Flow Restriction Therapy to Avoid Muscle Atrophy -- Section IV - Return to Sport Advanced Training Concepts -- 13.Current Concepts of Plyometric Exercise -- 14.Sportsmetrics Neuromuscular Training: Basic and Advanced -- 15.Important Steps for Return to Sport -- 16."Re-establishing Neurocognitive Function: Attentional Focus and Visual-Motor Training Neurocognitive Prinicples for ACL Rehabilitation and Re-Injury Risk Reduction (?? Title)" -- 17. Return to Sport for Soccer and Basketball.-18.Return to Sport for Tennis -- Section V - Objective Testing -- 19.The Physician’s Comprehensive Examination for Return to Sport -- 20.Neuromuscular Function, Agility, and Aerobic Testing -- 21.Muscle Strength and Dynamic Balance Stability Tests -- 22.Neurocognitive Testing -- Section VI - Psychological Readiness -- 23.Validated Questionnaires to Measure Return to Sport and Psychological Factors -- 24.Return to Sport Psychological and Psychosocial Issues in the Athlete: Identification and Management of Psychosocial Issues in the Athlete for Return to Sport -- Section VII - Other Knee Operations -- 25.Return to Sport After ACL Revision Reconstruction: Is It Advisable? -- 26.Return to Sport Considerations in the Pre-Adolescent Athlete -- 27.Return to Sport After Meniscus Operations: Meniscectomy, Repair, and Transplantation -- 28.Return to Sport After Patellofemoral Realignment -- 29.Return to Sport After Articular Cartilage Restorative Procedures -- 30.Return to Sport After Unicondylar, Patellofemoral, and Total Knee Arthroplasty. |
| Record Nr. | UNINA-9910357828803321 |
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2019 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Soggetto topico
-
Terapèutica
(56)
- Diagnòstic (10)
- Medicina preventiva (6)
- COVID-19 (4)
- Cancer Therapy (4)